Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. | Br J Pharmacol;166(1): 177-93, 2012 May. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.

May, R D; Monk, P D; Cohen, E S; Manuel, D; Dempsey, F; Davis, N H E; Dodd, A J; Corkill, D J; Woods, J; Joberty-Candotti, C; Conroy, L A; Koentgen, F; Martin, E C; Wilson, R; Brennan, N; Powell, J; Anderson, I K.

Affiliation

May RD; MedImmune, Abington, Cambridge, UK. mayr@medimmune.com

Br J Pharmacol ; 166(1): 177-93, 2012 May.

Article in En | MEDLINE | ID: mdl-21895629

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Interleukin-13 / Inflammation / Antibodies, Monoclonal Limits: Adolescent / Animals / Female / Humans / Male Language: En Journal: Br J Pharmacol Year: 2012 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Interleukin-13 / Inflammation / Antibodies, Monoclonal Limits: Adolescent / Animals / Female / Humans / Male Language: En Journal: Br J Pharmacol Year: 2012 Document type: Article Affiliation country: Country of publication: